Collectively, these findings highlight dual inhibition of FTO and BTK as a promising therapeutic strategy for maintaining low c-Myc and E2F1 expression levels, thereby improving survival outcomes and guiding future clinical management of breast cancer. This evidence concerns the gene E2F1 and breast cancer.